Menu
Search
|

Menu

Close
X

Mylan NV MYL.OQ (NASDAQ Stock Exchange Global Select Market)

38.31 USD
-0.32 (-0.83%)
As of Jun 22
chart
Previous Close 38.63
Open 38.95
Volume 2,545,018
3m Avg Volume 1,530,858
Today’s High 38.98
Today’s Low 38.11
52 Week High 47.81
52 Week Low 29.44
Shares Outstanding (mil) 515.45
Market Capitalization (mil) 19,746.70
Forward P/E 24.22
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 20 analysts

KEY STATS

Revenue (mm, USD)
FY18
2,684
FY17
11,908
FY16
11,077
FY15
9,429
EPS (USD)
FY18
0.169
FY17
1.537
FY16
0.907
FY15
1.664
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
24.22
34.14
Price to Sales (TTM)
vs sector
1.66
8.17
Price to Book (MRQ)
vs sector
1.50
4.30
Price to Cash Flow (TTM)
vs sector
7.44
22.70
Total Debt to Equity (MRQ)
vs sector
114.84
17.55
LT Debt to Equity (MRQ)
vs sector
94.50
13.12
Return on Investment (TTM)
vs sector
2.89
13.10
Return on Equity (TTM)
vs sector
6.81
15.09

EXECUTIVE LEADERSHIP

Robert Coury
Non-Executive Chairman of the Board, Since 2016
Salary: $1,627,000.00
Bonus: $947,398.00
Rajiv Malik
President, Executive Director, Since 2016
Salary: $1,000,000.00
Bonus: $1,459,380.00
Heather Bresch
Chief Executive Officer, Executive Director, Since 2016
Salary: $1,300,000.00
Bonus: $2,276,620.00
Kenneth Parks
Chief Financial Officer, Since 2016
Salary: $346,154.00
Bonus: $700,500.00
Dennis Zeleny
Chief Human Resource Officer, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

Unit 4, Trident Place, Mosquito
HATFIELD     AL10 9UL

Phone: +441707.853000

Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic, brand name and over-the-counter (OTC) products in a range of dosage forms and therapeutic categories. It operates through three segments on a geographic basis, North America, Europe and Rest of World. The Company's Cold-EEZE family of brands includes OTC cold remedies sold as lozenges, gummies, oral sprays, caplets, QuickMelts and oral liquid dose forms in the United States. The North America segment primarily develops, manufactures, sells and distributes pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized and cream or ointment form. The Europe segment sells pharmaceuticals under their International Nonproprietary Name (INN), such as active pharmaceutical ingredient (API), in certain European countries. The Rest of World segment is primarily made up of its operations in India, Australia, Japan and New Zealand.

SPONSORED STORIES